English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 909604      Online Users : 825
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13807


    Title: Is pathological T4a an independent indication of adjuvant therapy in buccal mucosal or gingival squamous cell carcinoma?
    Authors: Chao, TY;Chan, LP;Lee, HH;Kao, YH;Jhong, YP;Chiang, CH;Chuang, ST;Huang, CJ
    Contributors: NHRI Graduate Student Program
    Abstract: Background: To evaluate the clinicopathologic factors affecting the clinical outcomes in pathological T4aN0 (pT4aN0) buccal mucosal or gingival squamous cell carcinoma (SCC). Methods: This was a retrospective study of 113 consecutive patients with diagnoses of pT4aN0 buccal mucosal or gingival SCC between January 2010 and November 2018. The median follow-up was 38 months (range, 1–119 months). Kaplan-Meier and Cox proportional-hazards models were used for survival analysis. Results: In the entire study, 5-year overall survival (OS) and disease-free survival (DFS) rates were 73.7% and 83.6%, respectively. Univariate analysis revealed that lymphovascular invasion (LVI), perineural invasion (PNI), and margin status had significant effects on the DFS rate, and tumor cell differentiation had a significant effect on OS rate. Multivariate Cox regression analysis revealed margin status was the only significant factor affecting DFS. The patients (n=38) without the inadequate margin, LVI, PNI, and poorly differentiated tumor cells had a better 5-year DFS rate (P=0.023) whether they had received adjuvant treatment or not (91.5% versus 100%). However, no significant effect on the OS rate was found (P=0.544). Conclusions: The patients who had no adverse pathologic factors exhibited fair DFS rate without adjuvant therapy. The adjuvant therapy may not be considered for this subgroup.
    Date: 2021-09-30
    Relation: Therapeutic Radiology and Oncology. 2021 Sep 30;5(3):Article number 6920.
    Link to: http://dx.doi.org/10.21037/TRO-21-1
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85115983306
    Appears in Collections:[其他] 期刊論文

    Files in This Item:

    File Description SizeFormat
    SCP85115983306.pdf379KbAdobe PDF129View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback